Dr Lal Pathlabs Q1 FY26 Earnings Results

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. Presenting below are its Q1 FY26 earnings results.

 

Q1 FY26 Earnings Results

• Total Income: ₹670 crores, up 23.8% QoQ (Q4 FY25: ₹563.80 crores) and 11.3% YoY (Q1 FY25: ₹622.50 crores).

• Total Expenses: ₹518 crores, up 16.4% QoQ and 9.5% YoY.

• Profit Before Tax (PBT): ₹181.10 crores, up 51% QoQ (Q4 FY25: ₹119.90 crores) and 20.8% YoY (Q1 FY25: ₹149.90 crores).

• Tax Expense: ₹47.10 crores, up 38.1% QoQ and 11.9% YoY.

• Profit After Tax (PAT): ₹134.00 crores, up 56.2% QoQ (Q4 FY25: ₹85.80 crores) and 24.07% YoY (Q1 FY25: ₹107.80 crores).

• Earnings Per Share (EPS): ₹15.80, up 56.4% QoQ (Q4 FY25: ₹10.10) and 23.4% YoY (Q1 FY25: ₹12.80).

• EBITDA: ₹192 crores, up 13% YoY, margin steady at 28.7%.

• Revenue Growth Drivers: Growth driven by higher sample and patient volume increase of 10.7% and 5.3% respectively, and favorable test/product mix with bundled preventive health packages (Swasthfit portfolio contribution increased to 27% from 25%).

• Network Expansion: Added 18 new labs in FY25, with continued expansion focus in Tier 2, 3, and 4 towns; stronger presence in West and South India.

• Pricing: Stable pricing strategy with revenue per patient up 5.7% YoY due to premiumization and test mix shift, not from price hikes.

 

Management Commentary & Strategic Highlights

• Management noted robust operational execution delivering strong margin and profitability expansion.

• Revenue growth and margin trajectory are underpinned by digital transformation initiatives, volume-led growth, and broad-based demand recovery.

• Guidance remains stable with expected revenue growth of 11–12% and EBITDA margin slightly above prior outlook of 27% for FY26.

• Focus on preventive health and packaged offerings to drive long-term sustainable growth.

• Commitment to quality and extensive network accessibility reaffirmed as a competitive advantage.

 

 

Q4 FY25 Earnings Results

• Total Income: ₹603 crores.

• Profit After Tax (PAT): ₹156 crores.

• EPS: ₹18.52.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.